Shanghai Ruoyi Biotechnology
Developing consumer-oriented drugs, with a core pipeline of third-generation recombinant botulinum toxin, leveraging synthetic biology and AI-driven protein design platforms
About Shanghai Ruoyi Biotechnology
Shanghai Ruoyi Biotechnology Co., Ltd. (Asiflyer Bio) is a Chinese biotech incorporated in January 2018 that develops consumer-oriented protein drugs, led by a third-generation recombinant botulinum toxin pipeline for aesthetic and therapeutic use (candidates AFB-ZBZ(MD), AFB-ZBZ(KD) and AFB-ZBZ(MG)). Its platforms include a zinc-finger protein intracellular delivery system, an insect cell-baculovirus expression system and AI-assisted protein design. Originally based in Pudong, Shanghai, the company now has its headquarters in Kunshan, Suzhou (Jiangsu). It has raised several early rounds, including a CNY 50m angel round led by Yuansheng BioVenture in March 2022 and later seed financing from investors such as DNE Group and the Kunshan Angel Fund.
Source: Dealroom company dataNews
Open roles
Shanghai Ruoyi Biotechnology in the Suzhou Shi ecosystem
The Shanghai Ruoyi Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Yuansheng BioVenture- DGDNE Group
Series A1 investor entered at this stage
- KCKunshan Guoke Venture Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Shanghai Ruoyi Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shanghai Ruoyi Biotechnology on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
